Compare CRVS & IQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRVS | IQ |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Electronics/Video Chains |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2016 | 2017 |
| Metric | CRVS | IQ |
|---|---|---|
| Price | $12.68 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $30.17 | $2.91 |
| AVG Volume (30 Days) | 1.3M | ★ 5.5M |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.04 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $0.28 |
| Revenue Next Year | N/A | $3.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $0.98 |
| 52 Week High | $26.95 | $2.76 |
| Indicator | CRVS | IQ |
|---|---|---|
| Relative Strength Index (RSI) | 52.58 | 41.53 |
| Support Level | $11.13 | $1.03 |
| Resistance Level | $14.00 | $1.19 |
| Average True Range (ATR) | 0.66 | 0.04 |
| MACD | 0.24 | 0.00 |
| Stochastic Oscillator | 83.26 | 48.58 |
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.